Molina Healthcare, Inc. (MOH)

FairStock Score: 47/100 — MIXED

Key Financials

Strengths

• Large market cap ($7.5B) with established 44-year operating history and 19,000 employees providing stability
• Moderate leverage at 0.99 D/E ratio provides financial flexibility if operations stabilize
• Operates in essential Medicaid/Medicare sectors with structural demand tailwinds from aging population
• Low beta of 0.50 suggests relatively defensive positioning in broader healthcare sector

Concerns

• Q4 2025 operating loss of $160M on $11.4B revenue signals fundamental operational deterioration
• Negative free cash flow of -$100M indicates company is burning rather than generating cash
• Piotroski F-Score of 1/9 and Altman Z-Score of 1.80 point to financial distress and declining quality
• ROCE of only 3.14% is unacceptably low, suggesting capital is being destroyed rather than deployed efficiently

AI Analysis

Molina Healthcare presents a deeply troubled investment picture that violates several fundamental principles I hold dear. While the company operates in a structurally sound industry—managed care for Medicaid and Medicare populations—the recent financial deterioration is alarming. The latest quarter shows a net loss of $160 million on $11.4 billion in revenue, a -1.41% margin that suggests operational breakdown, not temporary cyclicality. The Piotroski F-Score of 1/9 is among the worst I've seen, indicating severely declining financial quality. Most concerning is the negative free cash flow of -$100 million with a -4.0% FCF yield—this company is burning cash, not generating it. The Altman Z-Score of 1.80 places it in the distress zone. While the P/E of 15.63 appears reasonable on the surface, it masks an unprofitable recent quarter. The 52-week range of $121-$360 suggests investors previously priced in very different expectations. The leverage ratio of 0.99 D/E is manageable, but profitability must be restored before debt becomes dangerous. I see a company facing severe operational challenges—likely from Medicaid rate compression, medical cost inflation, or both. The low beta of 0.50 provides no comfort when the fundamental business is deteriorating. Without clear evidence of turnaround momentum and return to sustainable profitability, this appears to be a value trap masquerading as a bargain.

Bull Case

Molina's valuation could offer deep value if recent losses prove temporary and reflect one-time medical cost spikes that are reversing. If management executes a successful operational turnaround and returns to historical profitability levels, the stock could re-rate significantly higher given the recent P/E compression.

Bear Case

The negative cash flow, deteriorating margins, and F-Score suggest structural problems in the Medicaid business model that may persist. If medical costs remain elevated and Medicaid rates don't improve, losses could deepen, forcing covenant violations or equity raises that devastate existing shareholders.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer